Physician profile
Jonathan Dvorak
NPI 1912432386
$727.01
in general payments reported to CMS, 2019-2025
14 companies · $239 in 2025
The $239 reported for 2025 was more than what a typical General Practice provider received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $350 · 2024: $138 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $131.65 | 2021-2025 | Entyvio |
| Abbvie INC. | $125.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $116.57 | 2024 | Zeposia |
| Boston Scientific Corporation | $73.34 | 2025 | General - Hemostasis, General - Enteral Feeding |
| Janssen Biotech, INC. | $42.70 | 2024-2025 | Tremfya |
| Pharming Healthcare, INC. | $42.22 | 2021 | |
| Glaxosmithkline, LLC. | $35.55 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $28.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $26.71 | 2021 | |
| Pfizer INC. | $25.08 | 2021 | |
| Alk-Abello, INC | $24.80 | 2021 | |
| Aimmune Therapeutics, INC. | $19.79 | 2021 | |
| Biocryst US Sales Co., LLC | $19.30 | 2021 | |
| Kaleo, INC. | $15.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Dvorak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.